Thomas A. Waldmann (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Thomas A. Waldmann" in English language version.

refsWebsite

Global rank English rank

22nih.gov

4^th place

10doi.org

2^nd place

1cancer.gov

1,684^th place

1,350^th place

1annualreviews.org

3,867^th place

3,957^th place

annualreviews.org (Global: 3,867^th place; English: 3,957^th place)

Waldmann, Thomas A. (April 2003). "Bio". Annual Review of Immunology. 21 (1): 1–27. doi:10.1146/annurev.immunol.21.120601.140933. PMID 12359737. Retrieved 2021-02-22.

cancer.gov (Global: 1,684^th place; English: 1,350^th place)

ccr.cancer.gov

"Thomas A. Waldmann, M.D. | Center for Cancer Research – National Cancer Institute". Ccr.cancer.gov. Retrieved 2021-02-22.

doi.org (Global: 2^nd place; English: 2^nd place)

Waldmann, Thomas A. (April 2003). "Bio". Annual Review of Immunology. 21 (1): 1–27. doi:10.1146/annurev.immunol.21.120601.140933. PMID 12359737. Retrieved 2021-02-22.
Bielekova, B; Richert, N; Howard, T; Blevins, G; Markovic-Plese, S; McCartin, J; Frank, JA; Würfe, J; Ohayon, J; Waldmann, TA; McFarland, HF; Martin, R (2004). "Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-beta". Proc Natl Acad Sci USA. 101 (23): 8705–8708. doi:10.1073/pnas.0402653101. PMC 423259. PMID 15161974.
Janik, JE; Morris, JC; O'Mahony, D; Pittaluga, S; Jaffe, ES; Redon, CE; Bonner, WM; Brechbiel, MW; Paik, CH; Whatley, M; Chen, C; Lee-J-H, Fleisher TA; Brown, M; White, JD; Stewart, DM; Fioravanti, S; Lee, CC; Goldman, CK; Bryant, BR; Junghans, RP; Carrasquillo, JA; Worthy, TY; Corcoran, E; Conlon, KC; Waldmann, TA (2015). "90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma". Proc Natl Acad Sci USA. 112 (42): 13045–13050. doi:10.1073/pnas.1516107112. PMC 4620907. PMID 26438866.
Burton, JD; Bamford, RN; Peters, C; Grant, AJ; Kurys, G; Goldman, CK; Brennan, J; Roessler, E; Waldmann, TA (1994). "A lymphokine, provisionally designated interleukin-T, produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells". Proc Natl Acad Sci USA. 91 (11): 4935–4939. doi:10.1073/pnas.91.11.4935. PMC 43904. PMID 8197160.
Bamford, RN; Grant, AJ; Burton, JD; Peters, C; Kurys, G; Goldman, CK; Brennan, J; Roessler, E; Waldmann, TA (1994). "The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells". Proc Natl Acad Sci USA. 91 (11): 4940–4944. doi:10.1073/pnas.91.11.4940. PMC 43905. PMID 8197161.
Conlon, KC; Lugli, E; Welles, HC; Rosenberg, SA; Fojo, AT; Morris, JC; Fleisher, TA; Dubois, SP; Perera, LP; Stewart, DM; Goldman, CK; Bryant, BR; Decker, JM; Chen, J; Worthy, TYA; Figg, WD Sr; Peer, CJ; Sneller, MC; Lane, HC; Yovandich, JL; Creekmore, SP; Roederer, M; Waldmann, TA (2015). "Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer". J Clin Oncol. 33 (1): 74–82. doi:10.1200/JCO.2014.57.3329. PMC 4268254. PMID 25403209.
Perera, LP; Waldmann, TA; Mosca, JD; Baldwin, N; Berzofsky, JA; Oh, SK (2007). "Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice". J Virol. 81 (16): 8774–8783. doi:10.1128/JVI.00538-07. PMC 1951366. PMID 17553867.
Poon, LLM; Leung, YHC; Nicholls, JM; Perera, P-Y; Lichy, JH; Yamamoto, M; Waldmann, TA; Peiris, JSM; Perera, LP (2009). "Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice". J Immunol. 182 (5): 3063–3071. doi:10.4049/jimmunol.0803467. PMC 2656349. PMID 19234203.
Berkowitz, JL; Janik, JE; Stewart, DM; Jaffe, ES; Stetler-Stevenson, M; Shih, JH; Fleisher, TA; Turner, M; Urquhart, NE; Wharfe, GH; Figg, WD; Peer, CJ; Goldman, CK; Waldmann, TA; Morris, JC (2014). "Safety, efficacy and pharmacokinetics/pharmacodynamics, of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma". Clin Immunol. 155 (2): 176–187. doi:10.1016/j.clim.2014.09.012. PMC 4306230. PMID 25267440.
Korsmeyer, SJ; Arnold, A; Bakhshi, A; Ravetch, JV; Siebenlist, U; Hieter, PA; Sharrow, SO; LeBien, TW; Kersey, JH; Poplack, DG; Leder, P; Waldmann, TA (1983). "Immunoglobulin gene rearrangement and cell surface antigen expression of acute lymphocyte leukemias of T-cell and B-cell precursor origins". J Clin Invest. 71 (2): 301–313. doi:10.1172/jci110770. PMC 436868. PMID 6401769.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Waldmann, Thomas A. (April 2003). "Bio". Annual Review of Immunology. 21 (1): 1–27. doi:10.1146/annurev.immunol.21.120601.140933. PMID 12359737. Retrieved 2021-02-22.
Uchiyama, T; Broder, S; Waldmann, TA (1981). "A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells". J Immunol. 126 (4): 1393–1397. PMID 6970774.
Waldmann, TA; Goldman, CK; Bongiovanni, KF; Sharrow, SO; Davey, MP; Cease, KB; Greenberg, SJ; Longo, DL (1988). "Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2". Blood. 72 (5): 1805–1816. PMID 2846094.
Bielekova, B; Richert, N; Howard, T; Blevins, G; Markovic-Plese, S; McCartin, J; Frank, JA; Würfe, J; Ohayon, J; Waldmann, TA; McFarland, HF; Martin, R (2004). "Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-beta". Proc Natl Acad Sci USA. 101 (23): 8705–8708. doi:10.1073/pnas.0402653101. PMC 423259. PMID 15161974.
Janik, JE; Morris, JC; O'Mahony, D; Pittaluga, S; Jaffe, ES; Redon, CE; Bonner, WM; Brechbiel, MW; Paik, CH; Whatley, M; Chen, C; Lee-J-H, Fleisher TA; Brown, M; White, JD; Stewart, DM; Fioravanti, S; Lee, CC; Goldman, CK; Bryant, BR; Junghans, RP; Carrasquillo, JA; Worthy, TY; Corcoran, E; Conlon, KC; Waldmann, TA (2015). "90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma". Proc Natl Acad Sci USA. 112 (42): 13045–13050. doi:10.1073/pnas.1516107112. PMC 4620907. PMID 26438866.
Burton, JD; Bamford, RN; Peters, C; Grant, AJ; Kurys, G; Goldman, CK; Brennan, J; Roessler, E; Waldmann, TA (1994). "A lymphokine, provisionally designated interleukin-T, produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells". Proc Natl Acad Sci USA. 91 (11): 4935–4939. doi:10.1073/pnas.91.11.4935. PMC 43904. PMID 8197160.
Bamford, RN; Grant, AJ; Burton, JD; Peters, C; Kurys, G; Goldman, CK; Brennan, J; Roessler, E; Waldmann, TA (1994). "The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells". Proc Natl Acad Sci USA. 91 (11): 4940–4944. doi:10.1073/pnas.91.11.4940. PMC 43905. PMID 8197161.
Dubois, S; Mariner, J; Waldmann, TA Tagaya Y (2002). "IL-15R alpha recycles and presents IL-15 in trans to neighboring cells". Immunity. 17 (5): 537–547. PMID 12433361.
Conlon, KC; Lugli, E; Welles, HC; Rosenberg, SA; Fojo, AT; Morris, JC; Fleisher, TA; Dubois, SP; Perera, LP; Stewart, DM; Goldman, CK; Bryant, BR; Decker, JM; Chen, J; Worthy, TYA; Figg, WD Sr; Peer, CJ; Sneller, MC; Lane, HC; Yovandich, JL; Creekmore, SP; Roederer, M; Waldmann, TA (2015). "Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer". J Clin Oncol. 33 (1): 74–82. doi:10.1200/JCO.2014.57.3329. PMC 4268254. PMID 25403209.
Perera, LP; Waldmann, TA; Mosca, JD; Baldwin, N; Berzofsky, JA; Oh, SK (2007). "Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice". J Virol. 81 (16): 8774–8783. doi:10.1128/JVI.00538-07. PMC 1951366. PMID 17553867.
Poon, LLM; Leung, YHC; Nicholls, JM; Perera, P-Y; Lichy, JH; Yamamoto, M; Waldmann, TA; Peiris, JSM; Perera, LP (2009). "Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice". J Immunol. 182 (5): 3063–3071. doi:10.4049/jimmunol.0803467. PMC 2656349. PMID 19234203.
Berkowitz, JL; Janik, JE; Stewart, DM; Jaffe, ES; Stetler-Stevenson, M; Shih, JH; Fleisher, TA; Turner, M; Urquhart, NE; Wharfe, GH; Figg, WD; Peer, CJ; Goldman, CK; Waldmann, TA; Morris, JC (2014). "Safety, efficacy and pharmacokinetics/pharmacodynamics, of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma". Clin Immunol. 155 (2): 176–187. doi:10.1016/j.clim.2014.09.012. PMC 4306230. PMID 25267440.
Korsmeyer, SJ; Arnold, A; Bakhshi, A; Ravetch, JV; Siebenlist, U; Hieter, PA; Sharrow, SO; LeBien, TW; Kersey, JH; Poplack, DG; Leder, P; Waldmann, TA (1983). "Immunoglobulin gene rearrangement and cell surface antigen expression of acute lymphocyte leukemias of T-cell and B-cell precursor origins". J Clin Invest. 71 (2): 301–313. doi:10.1172/jci110770. PMC 436868. PMID 6401769.

ncbi.nlm.nih.gov

Bielekova, B; Richert, N; Howard, T; Blevins, G; Markovic-Plese, S; McCartin, J; Frank, JA; Würfe, J; Ohayon, J; Waldmann, TA; McFarland, HF; Martin, R (2004). "Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-beta". Proc Natl Acad Sci USA. 101 (23): 8705–8708. doi:10.1073/pnas.0402653101. PMC 423259. PMID 15161974.
Janik, JE; Morris, JC; O'Mahony, D; Pittaluga, S; Jaffe, ES; Redon, CE; Bonner, WM; Brechbiel, MW; Paik, CH; Whatley, M; Chen, C; Lee-J-H, Fleisher TA; Brown, M; White, JD; Stewart, DM; Fioravanti, S; Lee, CC; Goldman, CK; Bryant, BR; Junghans, RP; Carrasquillo, JA; Worthy, TY; Corcoran, E; Conlon, KC; Waldmann, TA (2015). "90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma". Proc Natl Acad Sci USA. 112 (42): 13045–13050. doi:10.1073/pnas.1516107112. PMC 4620907. PMID 26438866.
Burton, JD; Bamford, RN; Peters, C; Grant, AJ; Kurys, G; Goldman, CK; Brennan, J; Roessler, E; Waldmann, TA (1994). "A lymphokine, provisionally designated interleukin-T, produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells". Proc Natl Acad Sci USA. 91 (11): 4935–4939. doi:10.1073/pnas.91.11.4935. PMC 43904. PMID 8197160.
Bamford, RN; Grant, AJ; Burton, JD; Peters, C; Kurys, G; Goldman, CK; Brennan, J; Roessler, E; Waldmann, TA (1994). "The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells". Proc Natl Acad Sci USA. 91 (11): 4940–4944. doi:10.1073/pnas.91.11.4940. PMC 43905. PMID 8197161.
Conlon, KC; Lugli, E; Welles, HC; Rosenberg, SA; Fojo, AT; Morris, JC; Fleisher, TA; Dubois, SP; Perera, LP; Stewart, DM; Goldman, CK; Bryant, BR; Decker, JM; Chen, J; Worthy, TYA; Figg, WD Sr; Peer, CJ; Sneller, MC; Lane, HC; Yovandich, JL; Creekmore, SP; Roederer, M; Waldmann, TA (2015). "Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer". J Clin Oncol. 33 (1): 74–82. doi:10.1200/JCO.2014.57.3329. PMC 4268254. PMID 25403209.
Perera, LP; Waldmann, TA; Mosca, JD; Baldwin, N; Berzofsky, JA; Oh, SK (2007). "Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice". J Virol. 81 (16): 8774–8783. doi:10.1128/JVI.00538-07. PMC 1951366. PMID 17553867.
Poon, LLM; Leung, YHC; Nicholls, JM; Perera, P-Y; Lichy, JH; Yamamoto, M; Waldmann, TA; Peiris, JSM; Perera, LP (2009). "Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice". J Immunol. 182 (5): 3063–3071. doi:10.4049/jimmunol.0803467. PMC 2656349. PMID 19234203.
Berkowitz, JL; Janik, JE; Stewart, DM; Jaffe, ES; Stetler-Stevenson, M; Shih, JH; Fleisher, TA; Turner, M; Urquhart, NE; Wharfe, GH; Figg, WD; Peer, CJ; Goldman, CK; Waldmann, TA; Morris, JC (2014). "Safety, efficacy and pharmacokinetics/pharmacodynamics, of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma". Clin Immunol. 155 (2): 176–187. doi:10.1016/j.clim.2014.09.012. PMC 4306230. PMID 25267440.
Korsmeyer, SJ; Arnold, A; Bakhshi, A; Ravetch, JV; Siebenlist, U; Hieter, PA; Sharrow, SO; LeBien, TW; Kersey, JH; Poplack, DG; Leder, P; Waldmann, TA (1983). "Immunoglobulin gene rearrangement and cell surface antigen expression of acute lymphocyte leukemias of T-cell and B-cell precursor origins". J Clin Invest. 71 (2): 301–313. doi:10.1172/jci110770. PMC 436868. PMID 6401769.

Thomas A. Waldmann (English Wikipedia)

annualreviews.org (Global: 3,867th place; English: 3,957th place)

cancer.gov (Global: 1,684th place; English: 1,350th place)